



Less stress, pure success... in your O.R. day¹



OMIDRIA[®]
(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

OMIDRIA HAS CONTINUED SEPARATE PAYMENT UNDER CMS IN ASCs²

- In its final rule under the Medicare OPSS for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment under the non-opioid pain management policy when used in the ASC setting. Separate payment for OMIDRIA is effective retroactively beginning October 1, 2020



A UNIQUE PERMANENT BILLING CODE FOR OMIDRIA: J1097^{3*}

- OMIDRIA is reimbursed per mL; therefore, providers should always use 1 mL as the billing unit and bill for 4 units
- ASCs use this unique permanent HCPCS code to bill CMS and other payers for separate payment
- HOPDs use this unique HCPCS code to bill commercial payers and Med Advantage

OPSS=Outpatient Prospective Payment System; CMS=Centers for Medicare & Medicaid Services; ASC=ambulatory surgery center; HCPCS=Healthcare Common Procedure Coding System; HOPD=hospital outpatient department.

*Individual plan coverage, payment, policies, and procedures vary and should be confirmed by the facility. Omeros does not guarantee reimbursement.

OMIDRIA DILUTION AND STORAGE⁴

Prior to dilution

- Store at 20°C to 25°C (68°F to 77°F)
- Protect from light

Easy to integrate into routine operating procedures


- Add preoperatively to irrigation solution
 - One 4-mL single-patient-use vial to 500 mL ophthalmic irrigating solution

Do not use if the solution is cloudy or contains particulate matter

After dilution, product can be stored:

Up to 4 hours
at room temperature

Up to 24 hours
if refrigerated



OMIDRIA**Assure**[®]

COVERAGE WITH CONFIDENCE

Omeros continues to support access to OMIDRIA through this Comprehensive Patient Assistance and Reimbursement Program.



Talk to your OMIDRIA representative or reimbursement specialist today or call 1-877-OMIDRIA (1-877-664-3742) 9 am-5 pm ET, Monday-Friday

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure to phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at $\geq 2\%$ are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

ORDERING INFORMATION FOR OMIDRIA



NDC#	PRODUCT	UNIT QUANTITY	CASE QUANTITY
62225-600-04	OMIDRIA is supplied in a clear, 5-mL glass, single-patient-use vial containing 4 mL of sterile solution. The smallest sellable unit is a carton, which contains four (4) single-patient-use vials.	One (1) carton contains four (4) single-patient-use vials.	One (1) case contains thirty (30) cartons (120 total vials).



One (1) carton=minimum order. OMIDRIA is sold only in carton quantities. OMIDRIA is not sold in individual vial quantities.

OMIDRIA IS AVAILABLE THROUGH NATIONAL WHOLESALERS AND SPECIALTY DISTRIBUTORS

WHOLESALER/DISTRIBUTOR	ITEM ORDER NUMBER	CONTACT PHONE NUMBER
McKesson Specialty Distribution*	5005028	1-800-482-6700
McKesson Plasma and Biologics*	3507175	1-877-625-2566
Cardinal Health Specialty Distribution†	5071410	1-855-855-0708
Besse Medical	44567	1-888-767-7123
ASD Healthcare‡	44567	1-800-746-6273
FFF Enterprises, Inc	OMI060004	1-800-843-7477

*For customers of McKesson full-line wholesaler division, OMIDRIA is available for purchase through McKesson Specialty Distribution and McKesson Plasma and Biologics.

†For customers of Cardinal full-line wholesaler division, OMIDRIA is available for purchase through Cardinal Health Specialty Distribution.

‡For customers of AmerisourceBergen Corporation full-line wholesale division, OMIDRIA is available through ASD Healthcare and can be ordered using the PassPort ordering platform through AmerisourceBergen.

For more information about OMIDRIA, please call 1-844-OMEROS1 (1-844-663-7671), or visit www.omidria.com.

References: **1.** Omeros survey data on file. **2.** Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs. Baltimore, MD: Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services; December 2, 2020. CMS publications CMS-1736-FC and 1736-IFC. **3.** HCPCS quarterly update. CMS.gov. Available at: <https://www.cms.gov/medicare/coding/hcpcsreleasecodesets/hcpcs-quarterly-update.html>. Accessed August 9, 2019. **4.** OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017.



OMIDRIA®

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%



OMEROS®, the OMEROS logo®, OMIDRIA®, the OMIDRIA logo®, OMIDRIAssure®, and the OMIDRIAssure® logo are registered trademarks of Omeros Corporation.

© Omeros Corporation 2019, all rights reserved. US-OM-2000179